Raffaele Colombo/LinkedIn
May 17, 2025, 11:48
Raffaele Colombo: The Therapeutic Window of Antibody-Drug Conjugates
Raffaele Colombo, Associate Director, Medicinal Chemistry at Zymeworks Inc., posted on X:
“The tyranny of PBD ADCs: ADCT-602 has been discontinued!
My take for AACR25 educational session
Read more about ADC payload potency and MTD in our recent review, or in our Cancer Cell commentary.”
Title: The therapeutic window of antibody drug conjugates: A dogma in need of revision
Authors: Raffaele Colombo, Jamie R. Rich
Read The Full Article at Cancer Cell.
More posts featuring Raffaele Colombo.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 7, 2025, 17:41
Jun 7, 2025, 16:47
Jun 7, 2025, 16:40
Jun 7, 2025, 16:30
Jun 7, 2025, 16:07
Jun 7, 2025, 15:49